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The retinoic acid (RA) receptor (RAR) 82 promoter 
is strongly activated by RA in embryonal carcinoma 
(EC) cells. We examined this activation in the P19 
EC-derived END-2 cell line and in ElA-expressing 
counterparts and found strong RA-dependent 
RAR@2 promoter activation in the ElA-expressing 
cells, which was not observed in the parental cell 
line, indicating a possible role for ElA in RAR82 
activation. In transient transfection assays, ElA 
functioned as a coactivator of RA-dependent RARBS 
promoter activation and, moreover, was able to re- 
store this activation in cells lacking RARBP activa- 
tion. By deletion analysis, two regions in the RARBP 
promoter were identified that mediate the stimula- 
tory effect of ElA: the RA response element and 
TATA box-containing region and a more up-stream 
region between -180 and -63, in which a CAMP 
response element-related motif was identified as a 
target element for ElA. In addition, determination of 
endogenous ElA-like activity by measuring E2A pro- 
moter activity in transient transfection assays in EC 
and differentiated cells revealed a correlation be- 
tween RA-dependent RAR82 promoter activation 
and the presence of this activity, suggesting an 
important role for the cellular equivalent of ElA in 
regulation of the RAR82 promoter. (Molecular En- 
docrinology 7: 604-615, 1993) 
INTRODUCTION 
Retinoids are known to play an important role in many 
biological processes, such as cell growth, differentia- 
tion, and development (l-3). One of the most striking 
effects of the retinol metabolite retinoic acid (RA) is its 
ability to induce differentiation in embryonal carcinoma 
(EC) cells. The murine P19 EC cell line, for example, 
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which shares many characteristics with the pluripotent 
inner cell mass cells of the early mouse embryo, is able 
to differentiate into a variety of cell types upon the 
administration of RA (4, 5). The biological action of RA 
is mediated by two specific sets of nuclear retinoid 
receptors, RA receptors (RARs) anti retinoid X-recep- 
tors (RXRs), which belong to the multigene family of 
steroid/thyroid hormone receptors (for reviews, see 
Refs. 6-8). These receptors function as ligand-inducible 
transacting transcription factors and modulate the 
expression of target genes by interaction with specific 
&-acting DNA elements, the hormone response ele- 
ments. Both subfamilies of retinoid receptors consist of 
several receptor subtypes, referred to as RARa, -8, 
and -y (9-14) and RXRCI, $3, and -y (15-17). Recent 
studies have identified 9-ci.s RA as the natural ligand 
for RXRs (18, 19). 
The three RAR subtypes were found to be distinctly 
and spatio-temporally expressed during mouse embry- 
ogenesis (20-23) suggesting a specific role for each 
subtype in development. In addition, different isoforms 
of each RAR subtype have been identified, which differ 
in their N-terminal A region (13, 24-26). The mRNAs of 
these isoforms are generated by differential promoter 
usage and alternative splicing. For RAR& for example, 
three mouse mRNA isoforms (mRARP1, $2, and -p3) 
have been found that are transcribed from two different 
promoters in the same gene (26). The most up-stream 
located promoter is used for the transcription of 
mRNAp1 and $3, which are predominantly expressed 
in fetal and adult brain and thought to play a role in the 
development of the central nervous system. RARPP 
mRNA, transcribed from the other promoter, is highly 
expressed in RA-treated EC and embryonic stem cells, 
which suggests that this isoform may be important 
during early stages of development (26). 
In murine EC cells, RARa and -y are constitutively 
expressed, whereas the RAR/3 gene is rapidly and 
strongly induced after RA treatment (27, 28). This in- 
duction is due to transcriptional activation of the RARP2 
promoter, which contains a RARE positioned five nu- 
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cleotides in front of the TATA box (29, 30). The expres- 
sion of other genes, such as the laminin-Bl gene, is 
altered later during RA-induced differentiation of EC 
cells, generally some 24-48 h after RA addition (31). 
The promoter of the laminin-Bl gene was also found to 
contain a RARE, although different from the RARE 
identified in the RARPP promoter and with a lower 
affinity for RARs (32). Interesting in this respect is the 
identification of the so-called coregulators, proteins that 
are able to associate with RARs and thereby modulate 
their affinities for different RAREs (33). In fact, members 
of the RXR subfamily have been recently identified as 
coregulators of RAR action (17, 34-38). Adenovirus 
El A products are required for transactivation of aden- 
ovirus early genes. 
The role of ElA in cellular transformation has been 
well studied (for reviews, see Refs. 37 and 38). ElA 
alone has the property of immortalizing primary cells in 
culture (39, 40) and in cooperation with the adenoviral 
El B gene or an activated ras gene is capable of fully 
transforming cells (40, 41). The ElA transcription unit 
produces two major spliced mRNAs, the 12s and 13s 
forms, which encode proteins consisting of 243 and 
289 amino acids, respectively. These proteins are able 
to activate or repress the transcription of both cellular 
and viral genes (37, 42-45). Three regions (CRl-3) 
have been identified in the ElA 13s protein, which are 
highly conserved among the El A proteins from different 
adenoviruses. The El A 12s protein contains CR-1 and 
CR-2, which are required for cellular transformation, but 
lack CR-3, which is known to be necessary for tran- 
scriptional activation of viral early genes (for reviews, 
see Refs. 38 and 46). In general, the 13s ElA product 
is involved in the transactivation of target genes, while 
the 12s protein functions as a repressor. 
The molecular mechanism underlying gene regulation 
by El A is still not completely understood. Studies to 
unravel this mechanism have been made complicated 
by the failure to show that ElA could bind to specific 
DNA sequences (47, 48). However, analyses of the 
promoter regions of El A-inducible genes lead to the 
identification of a DNA element involved in mediating 
the effect of ElA on transcription. This element ap- 
peared to be identical to the CAMP response element 
(CRE) and binds the cellular transcription factor ATF or 
CRE-binding protein (CREB) (for review, see Ref. 38 
and references therein). In addition, for several genes, 
TATA-binding factors were found to play an important 
role in mediating the transactivation by ElA (43, 49- 
51). Apart from interactions with DNA-binding proteins, 
ElA was also shown to interact with other cellular 
proteins, among them the retinoblastoma gene product 
(52,53). These findings lead to the postulation that El A 
exerts its function through multiple cellular or viral pro- 
teins. 
In EC cells, the existence of an El A-like activity has 
been reported which is lost upon differentiation with RA 
(54, 55). This was based on the observation that the 
adenoviral E2A gene, expression of which requires the 
El A proteins, is active in EC cells (42) whereas, on the 
other hand, the polyoma virus enhancer, which is re- 
pressed by ElA (44, 56), also has reduced activity in 
undifferentiated cells, but becomes active upon differ- 
entiation (57-59). El A-like activity could also be de- 
tected in mouse oocytes and preimplantation-embryos 
(60, 61). However, the factors that form the basis of 
this El A-like activity have yet to be identified. In this 
report we studied RA-dependent RARP2 promoter ac- 
tivation in END-2 cells, a RA-differentiated derivative of 
P19 EC cells (62) and in END-2 ElA cells, which have 
been stably transfected with an El A expression vector 
(63). In contrast to the situation in END-2 cells, the 
RARP2 gene is strongly activated by RA in the El A- 
expressing derivatives, indicating a possible involve- 
ment of El A in RA-induced RARB2 promoter activation. 
To test this hypothesis, we performed transient trans- 
fection assays in several cell lines using RAR/32 pro- 
moter-containing reporter constructs and El A expres- 
sion vectors. We demonstrate that RA-dependent 
RARP2 promoter activation can be restored by cotrans- 
fection of ElA expression vectors in cells in which 
normally this activation is not observed. In addition, we 
show that two regions in the RARP2 promoter are 
involved in conferring the stimulatory effect of El A and 
RA. Finally, we postulate that the cellular equivalent of 
El A is able to function as a coregulator of RA-depend- 
ent RARP2 promoter activation. 
RESULTS 
RAR Expression in END-2 and END-2 ElA Cells 
P19 EC cells, which form a model system for studying 
early mouse embryogenesis, are tumorigenic cells and 
exhibit all of the characteristics of transformed cells, 
including anchorage-independent growth and prolifera- 
tion in the absence of growth factors. END-2 cells, 
cloned from P19 EC cells differentiated by aggregation 
in the presence of RA, have lost the transformed phe- 
notype and possess endoderm-like characteristics (62). 
From this cell line, three clones have been isolated that 
are stably transfected with the adenovirus type 5 El A 
gene, designated clones 20, 23, and 24. These clones, 
which express both ElA mRNA and protein, have re- 
gained some characteristics of EC cells and posses a 
more EC cell-like morphology (63). 
We questioned whether the El A-induced change in 
differentiation state in END-2 cells is accompanied by 
an altered expression pattern of RARs. To address this, 
we cultured END-2 and END-P-ElA cells for 0, 8, or 24 
h in the presence of RA and determined RAR expres- 
sion by RNase protection analyses using RARa-, -p-, 
and -r-specific complementary riboprobes, as de- 
scribed in Materials and Methods. Since these probes 
are directed against the C/D and E/F regions, all iso- 
forms present will be recognized. Figure 1 A shows that 
both the END-2 and END9-ElA cell lines contain a 
similar level of RARcv and -y transcripts in the absence 
of RA, and these transcript levels are not significantly 
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Fig. 1. AAR Expression in Untreated and RA-Treated END-2 and END-2 ElA Cell Lines 
A, RNA obtained from END-2 cells and three different END-P-El A clones treated for 0, 6, and 24 h with RA was simultaniously 
hybridized with RAR~Y, -@-, and -y- and GAPDH (gap)-specific riboprobes in a RNase protection analysis. As controls, lanes indicated 
(Y, j3, and y  show the protected mRNA fragments when the RARa, -8, and -y riboprobes were hybridized alone to RNA isolated 
from P19 EC cells treated for 24 h with RA. B, Relative RARB expression was determined by quantification of the RARp transcript 
levels shown in A and correction for the GAPDH transcript levels. 
affected by RA treatment. RARP transcripts could not 
be detected in untreated END-2 and END-P-ElA cells; 
however, RA treatment resulted in the induction of 
RAR/3 expression. Interestingly, this induction appeared 
to be stronger in the El A-expressing cell lines than in 
the parental END-2 cells (see also Fig. 1 B). 
RA-Dependent RAR82 Promoter Activation in END- 
2 and END-2 ElA Cells 
The strong RA-dependent increase in the amount of 
RARP transcripts in END-2 El A cells, which was ob- 
served to a lesser extent in the parental cell line END- 
2, suggested the possibility that stable expression of 
ElA affects this induction. We next investigated 
whether this was due to an enhanced transcriptional 
activation of the RAR/32 promoter in END9-ElA cells 
compared to the situation found in the parental END-2 
cell line. We, therefore, performed transient transfection 
assays with a chloramphenicol acetyltransferase (CAT) 
reporter construct containing the -1470/l 56 fragment 
of the human RARP2 promoter and determined CAT 
activity in untreated and RA-treated END-2 and END- 
2-El A cells. Figure 2 shows a strong RA-dependent 
increase in CAT activity on this construct in the ElA- 
expressing clones 20 and 23 and, to a lesser extent, in 
clone 24, while a much smaller induction is seen in 
END-2 cells. These results demonstrate that the en- 
hanced level of RA-induced RARP expression in the 
El A-expressing END-2 cells compared with the non- 
transfected END-2 cells is due to a stronger activation 
of the RARPP promoter by RA. 
The finding that the accumulation of RARB transcripts 
after RA treatment in the END-P-ElA cell lines (Fig. 1) 
is not completely consistent with the observed in- 
creases in CAT activity might be explained by differ- 
ences in transcript and/or protein stability in these cells. 
In addition, the variation found in the level of activation 
among the three END9-derived clones could be due to 
different levels of El A proteins expressed in each cell 
line (63). 
Effects of ElA 12s and 13s on RA-Dependent 
RARB2 Promoter Activation in Different Cell Types 
As mentioned previously, stable expression of El A in 
END-2 cells causes a change in their state of differen- 
tiation (63). Therefore, the enhanced RA-dependent 
RARP2 promoter activation observed in END9-El A 
cells could be due to an indirect effect of El A. To 
investigate whether El A affects the RARBP promoter 
more directly and to examine which ElA protein, the 
12s or the 13s form, enhances the level of RA-induced 
RAR@P transcription, we transfected END-2 cells with 
the -1470/156 CAT construct in combination with 1 
pg DNA ElA expression vectors and performed CAT 
assays in the absence and presence of RA. Interest- 
ingly, after RA treatment, cotransfection of the vector 
pE1 A 13s resulted in an increase in CAT activity, while 
a small repressive effect was observed when using the 
pE1 A 12s vector (Fig. 3). In the absence of RA, cotrans- 
fection of the El A expression vectors had no effect on 
the level of CAT activity (not shown). One microgram 
of ElA expression vector was used in these assays 
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Fig. 2. RA-Dependent RARfl2 Promoter Activation in END-2 
and END-P-ElA Cells 
Comparison of the level of RAdependent RARPP promoter 
activation by transient transfection assays in END-2 cells and 
in the three El A-expressing derivatives, clones 20, 23, and 
24, using a CAT reporter construct containing nucleotides 
-1470 to 156 of the human RARPP promoter. CAT activity 
was determined in extracts of untreated and RA-treated cells 
by determining the percent conversion of [‘4C]chloramphenicol 
to its acetylated products. A representative experiment is 
shown. 
because this amount appeared to give the optimal 
response in dose-response studies (not shown). A vec- 
tor containing a P-actin promoter-driven CAT gene 
served as a positive control in the assay. 
In addition, we studied the effects of both EIA prod- 
ucts on RA-dependent RARP2 promoter activation in 
two other cell lines: the human colon tumor cell line 
HCTI 16, in which RARP2 activation cannot normally 
be detected (van der Leede, B-j. M., in preparation), 
and PI9 EC cells, which show strong RA-dependent 
RARP2 promoter activation. Therefore, the CAT assays 
performed in END-2 cells were repeated in these cell 
lines. As shown in Fig. 3, in the absence of ElA 
expression vector, the RARP2 promoter is insensitive 
to the inducing effect of RA in HCTI 16 cells. However, 
cotransfection of pE1 A 13s enables the promoter to be 
activated by RA, whereas cotransfection of the pElA 
12s vector has no effect. 
In P19 EC cells, the EIA 12s product has a repres- 
sive effect on RA-induced CAT activity, while the 13s 
product leads to even stronger activation of the RARP2 
promoter by RA (Fig. 3). 
From these results it can be concluded that depend- 
ent on the cell lines used, 12s El A has no or a repres- 
sive effect on RA-dependent RARP2 promoter activa- 
607 
tion, while 13s EIA can stimulate and in other cases 
can restore this activation. 
Determination of ElA-Sensitive Regions in the 
RARB2 Promoter 
We next examined which sequences of the RARP2 
promoter are involved in conferring the stimulatoty or 
repressive effect of El A in transient transfection assays 
in the different cell lines. 
First, END-2-cl23 cells were transfected with several 
CAT reporter constructs containing 5’-progressive 
deletions of the -1470/l 56 RARP2 promoter fragment 
(Fig. 4A), and their activation by RA was determined. 
Figure 48 shows that constructs containing the se- 
quences between -180 and 156 have comparable lev- 
els of activation, while a 3- to 4-fold decrease in CAT 
activity is observed when the RARP2 promoter frag- 
ment encompassing nucleotides -180 to -63 is re- 
moved. In addition, the RARE-containing -63/l 56 frag- 
ment is sufficient for mediating RA-dependent activa- 
tion. 
Secondly, we transfected these deletion constructs 
in combination with the pE1 A 13s or pE1 A 12s vector 
in HCTI 16 cells (Fig. 4C). As described above for 
HCTI 16 cells, 12s El A had hardly any effect on RARP2 
promoter activation. Using pE1 A 13S, the levels of 
induction as measured on the -180/l 56 construct ap- 
peared to be similar to the levels found when the 
-1470/l 56 reporter was used. However, a 3-fold lower 
level of RA-induced CAT activity was observed on the 
-63/l 56 construct. As controls, expression of the 12s 
and 13s products in HCTI 16 cells in the absence of 
RA resulted in only a slight increase in the basal level 
of transcription in the case of 13s El A. 
Finally, in P19 EC cells, the -180/156 and -63/156 
CAT constructs were tested for activation by RA, while 
the amount of cotransfected pE1 A 12s and pE1 A 13s 
expression vector was varied. Figure 4D shows that 
the El A 13s product is able to enhance expression of 
the already strongly activated RARP2 promoter by 50- 
70% when 1.25 or 2.5 pg pE1 A 13s was cotransfected 
with the -180/156 reporter construct. Transfection of 
higher amounts of pE1 A 13s did not lead to higher 
levels of induction (not shown). In contrast, cotransfec- 
tion of the pE1 A 12s expression vector with the same 
reporter construct resulted in an approximately 50% 
reduction in RA-induced RARP2 promoter activation 
compared to the normal level of induction. Interestingly, 
when using the -631156 reporter construct, the EIA 
13s product had a repressive effect on activation of 
the promoter by RA, which was of the same order as 
the repression found with the El A 12s product on this 
reporter (Fig. 40). 
Taken together, the deletion studies in the El A stably 
transfected END-2cl23 cell line and the cotransfection 
experiments in HCTl16 and P19 EC cells show that 
two regions in the RARB2 promoter mediate the effects 
of El A and RA: the RARE containing -63/156 pro- 
moter fragment and sequences located between -180 
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Fig. 3. Comparative Analyses of RA-Dependent RARB2 Promoter Activation in END-2, HCTl16, and P19 EC Cells in CAT Assays 
upon Cotransfection with ElA Expression Vectors 
END-P, HCTl16, and P19 EC cells were transfected with the -1470/l 56 reporter construct alone or in combination with an El A 
12s or 13s expression vector, and CAT activity was determined in the presence or absence of RA. A representative experiment 
is shown. A @-actin-CAT reporter plasmid served as a positive control in the assay (C). 
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Fig. 4. Localization of RAR@2 Promoter Regions Mediating El A and RA-Dependent Activation 
A, Schematic representation of the human RARPP promoter-derived Y-progressive deletion CAT constructs. The relative 
positions of the up-stream stimulatory promoter region the RARE, the TATA box, and the 5’ends of the reporter constructs 
used in the experiments are indicated. B, CAT assays with the indicated reporter constructs in untreated and RA-treated END-P- 
cl23 cells. A representative experiment is shown. C, Cotransfection assays in the human colon tumor cell line HCTl16 with 1 fig 
ElA 12s or 13s expression vector in combination with the indicated reporters. The mean + SD of three independent experiments 
are shown. D, Cotransfection assays with the indicated reporter constructs and varying amounts of ElA expression vectors in P19 
EC cells. The level of RA-induced CAT activity is depicted as a percentage of the level of activity normally found in the absence of 
cotransfected ElA expression vectors (control). The mean f  SD of three independent experiments are shown. 
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and -63. Furthermore, the cotransfection experiments 
demonstrate that 13s ElA exerts its action via both 
promoter regions, while the repressive effect of ElA 
12s on RA-induced RARP2 promoter activation is me- 
diated by sequences located on the -63/l 56 fragment. 
However, there appear to be cell-specific factors able 
to modulate the effect of ElA on RARP2 promoter 
activation, because the El A 13s product functioned as 
a repressor in P19 EC cells on reporter constructs 
lacking the -180/-63 promoter fragment, whereas in 
HCTl16 cells, activation was restored. 
Identification of a CRE-Like Sequence as ElA 
Response Element 
In earlier studies in P19 EC cells, we found that besides 
the RARE, more up-stream located sequences are 
involved in both mouse and human RARP2 promoter 
activation by RA (28, 64). Moreover, we have recently 
identified an element, located at position -99 to -92 in 
the RARPP promoter, that enhances RA-dependent 
promoter activation (65). This element, designated 
CRE-82, is conserved in both the human and mouse 
RARB2 promoter and consists of the motif TGATGTCA, 
which closely resembles the CRE consensus 
TGACGTCA. We demonstrated that CRE-/I2 can bind 
members of the ATF/CREB transcription family (for 
review, see Ref. 66) by competition experiments in gel 
retardation assays using consensus CRE-containing 
oligonucleotides (65). A specific member, ATF-2, has 
been reported to mediate transcription activation by 
ElA (67). Besides CRE-P2, a second putative regula- 
tory element was localized on position -84 to -78 with 
homology to the TPA response element (TRE) or APl- 
binding site (68, 69). However, we could not find a role 
for this element, designated TRE-P2, in RA-dependent 
RARPP promoter activation in P19 EC cells. 
To examine whether these elements are involved in 
mediating the stimulatory effect of ElA on the -180/ 
-63 RARP2 promoter fragment, HCT116 cells were 
transfected with the -180/156 reporter construct in 
which either CRE+32 (ACRE) or TRE-@2 (ATRE) was 
mutated, and CAT activity was determined in the ab- 
sence or presence of El A expression vectors and RA. 
As observed earlier, no significant increases in CAT 
activity could be detected after RA treatment and/or 
cotransfection with pE1A 12s on any of the reporter 
constructs used (Fig. 5). Interestingly, upon cotransfec- 
tion with pE1A 13S, similar levels of RA-induced CAT 
activity were found on the -63/l 56 and ACRE reporter 
constructs, while the wild-type -180/l 56 construct 
mediated a 3-fold higher level of CAT activity. Mutation 
of TRE-/I2 did not affect the responses of the -180/ 
156 promoter fragment to El A 13s and RA. These 
results demonstrate that CRE-/32 mediates the stimu- 
latory effect of El A 13s on the -180/-63 region upon 
RA-dependent RARP2 promoter activation. 
ElA Enhances Protein Binding to the -180/-83 
RAW32 Promoter Region 
We next questioned whether there are differences in 
nuclear protein binding to the -180/-63 RAR@2 pro- 
moter region in P19 EC, END-2, and END-2-cl20 cells. 
To assess this, we performed gel retardation assays 
with 32P-labeled -1 SO/-63 promoter fragment and nu- 
clear extracts from these cells cultured in the presence 
or absence of RA. As shown in Fig. 6, predominantly 
two protein-DNA complexes, named 1 and 3, were 
found in nuclear extracts from untreated P19 EC cells. 
In extracts from P19 EC cells treated for 24 h with RA, 
an additional protein-DNA complex, called 2, could be 
clearly detected. In addition, upon longer periods of film 
exposure to the polyacrylamide gel used for the gel 
retardation assay, it appeared that a low amount of 
complex 2 is present in extracts from untreated P19 
EC cells (results not shown). Binding complexes 1 and 
3 were found in END-2 cell nuclear extracts, while 
complex 2 could not be detected in either untreated or 
RA-treated cells. The apparent increase in the amount 
of complexes 1 and 3 formed after RA treatment, as 
shown in Fig. 6, is due to a lower protein content of the 
extracts derived from untreated END-2 cells used in 
this experiment and is normally not observed. All three 
complexes were found in nuclear extracts from un- 
treated and RA-treated END-2-1~120 cells, and protein 
binding to the -180/-63 promoter region using these 
extracts appeared to be stronger than that in the ex- 
tracts derived from P19 EC and END-2 cells, which 
normally show similar levels of complex l- and 3-binding 
activities. 
Competition experiments using nuclear extracts from 
RA-treated END-2cl20 cells showed the specificity of 
the three binding complexes; binding activity was al- 
most completely lost when using an excess of cold 
probe, and nonspecific competition with a RARE-02 
containing oligonucleotide did not reduce binding. Inter- 
estingly, CRE$2-containing oligonucleotides specifi- 
cally competed for complex e-binding activity when 
using nuclear extracts from END-2cl20 and P19 EC 
cells (Fig. 7 and data not shown). TRE-82 oligonucleo- 
tides did not compete for any of the complexes (not 
shown). These findings suggest that there are addi- 
tional, yet unidentified, protein-binding sites localized 
on the -180/-63 RARP2 promoter fragment. 
Taken together, these results show that stable 
expression of ElA in END-2 cells increases the binding 
of complex 1- and 3-binding activities to the -180/-63 
RARpP promoter region and, moreover, induces protein 
binding to CRE-@2. Furthermore, RA treatment of P19 
EC cells enhances CRE-P2 binding, which was not 
observed in END-2- and END-2-cl20 cells. 
Correlation between RA-Dependent RAR82 
Promoter Activation and the Presence of Cellular 
ElA 
The results presented above show that El A can act as 
a coactivator of RA-dependent RARB2 promoter acti- 
vation. Since EC cells are thought to contain a cellular 
equivalent of El A which is lost upon differentiation, we 
postulate that the strong activation of the RARP2 pro- 
moter by RA in P19 EC cells could be facilitated by this 
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Fig. 5. A CRE-Related Sequence in the RARPP Promoter Is Responsive to El A 
Comparison of the level of RA-dependent RARP2 promoter activation on the -180/156, ACRE-, ATRE, and -63/156 CAT 
constructs upon cotransfection with 1 pg pE1 A 12s or 13s in HCTl16 EC cells. ACRE/CAT was generated by altering the CRE- 
related sequence TGATGTCA [wild type (WT)] at position -99 to -92 in the -180/l 56 construct into AGATGTTA by site-directed 
mutaqenesis. In a similar fashion, ATRE/CAT was constructed bv mutation of TRE-P2, TGGGTCA at position -84 to -78, into 
GTGGTCA. The mean r SEM of four independent experiments are shown. 
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Fig. 6. Stable Expression of El A in END-2 Cells Enhances 
Protein Binding to the -180/-63 RARBP Promoter Region 
Gel retardation assays with nuclear extracts (N.E.) from P19 
EC-, END-2-, and END-2-cl20 cells cultured in the absence or 
presence of RA (24 h) using radioactive labeled -180/-63 
RARBP promoter fragment as a probe. The three predominant 
protein-DNA compexes formed are numbered 1,2, and 3, and 
a nonspecific band is indicated by an asterisk. Competition 
(camp.) experiments (lOO-fold excess) were performed with 
cold -180/-63 fragment (specific) or CRE-/32 (CRE)- and 
RARE-p2 (RARE)-containing oligonucleotides. 
endogenous ElA-like factor. In addition, the weak re- 
sponse or even the insensitivity of the promoter to RA 
in differentiated (END-2 and HCT116) cells could then 
be explained by assuming that these cells contain only 
low amounts of this factor or are devoid of it. 
To determine whether there is a correlation between 
RA-dependent PIAFt/ promoter activation and the 
presence of an endogenous El A-substituting activity, 
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Fig. 7. Detection of El A-Like Activity in Several Cell Lines by 
Determination of E2A Promoter Activity 
The E2A promoter containing vector p2CAT and a vector 
containing a p-actin promoter-driven CAT gene were tran- 
siently transfected in the indicated cell lines. The activity of the 
E2A promoter was related to the activity of the p-actin pro- 
moter in the same cell line. The horizontal line represents the 
level at which E2A promoter activity equals @-actin promoter 
activity. As a control, p2CAT was cotransfected with the EiA 
expression vector pE1 A 13s (+ El A). The ratio indicated is 
the mean of three independent experiments. 
we monitored El A-like activity in the P19 EC, END-2, 
and HCT116 cell lines. Therefore, these cells were 
transfected with a CAT reporter construct containing 
the El A-dependent E2A promoter, the activity of which 
reflects the presence of El A-like activity, as has been 
demonstrated recently (70). Interestingly, in P19 EC 
cells, the E2A promoter appeared to be as active as in 
the El A-expressing human fetal kidney cell line 293 
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(71) (Fig. 7). In this cell line, the RARP2 promoter can 
also be strongly activated by RA (not shown). In END- 
2-ElAcl23 cells, strong E2A promoter activity was 
observed, while much lower levels of activity were 
detected in the END-2 and HCT116 cell lines (7% and 
5%, respectively, of that in 293 cells). Cotransfection 
of the expression vector pE1 A 13s resulted in an 
increase in E2A promoter activity, most profoundly in 
the END-2 and HCTl16 cell lines, and to a lesser extent 
in the El A-expressing cell lines and P19 EC cells. 
These data indicate the presence of a high level of 
El A-like activity in P19 EC cells and much lower levels 
in END-2 and HCT116 cells, supporting our hypothesis 
that this factor functions as a coactivator of RA-de- 
pendent RARBP promoter activation. 
DISCUSSION 
RA-induced differentiation of P19 embryonal carcinoma 
cells is accompanied by strong transactivation of the 
RARP2 promoter by ligand-activated RARs, mediated 
by a RARE located in the proximity of the TATA box. 
We examined RA-dependent RARP2 promoter activa- 
tion in the RAdifferentiated P19 EC-derived END-2 cell 
line (62) and in their El A-transfected clonal derivatives 
(63) and found strong activation in the El A-containing 
cells that was not observed in the parental cell line 
(Figs. 1 and 2). This result prompted us to investigate 
whether ElA can function as a coactivator of RA- 
dependent RAR/32 promoter activation. A comparative 
analysis of promoter activation in END-P, HCT116, and 
P19 EC cells by transient transfection assays using 
El A expression vectors showed that the El A 13s 
product enhances or restores RARP2 promoter activa- 
tion in these cell lines, while the El A 12s product either 
has no or a repressive effect (Fig. 3). In both END-B 
El A stable transfectants and cotransfection experi- 
ments in P19 EC and HCT116 cells, deletion analysis 
of the RARj32 promoter revealed the presence of two 
El A-responsive regions; a 117-basepair (bp) fragment 
between -180 and -63 and a fragment that contains 
the RARE and the TATA element (Fig. 4). In addition, a 
CRE-related sequence at position -99 to -92 in the 
117-bp fragment was identified as an El A response 
element (Fig. 5). Protein binding studies to the -180/ 
-63 promoter region in gel retardation experiments 
with nuclear extracts from different cell lines showed 
that CRE-PBbinding activity is enhanced after RA treat- 
ment in P19 EC cells, which was not the case in END- 
2 and END-BE1 A cells, and that El A increases protein 
binding to the -180/-63 fragment (Fig. 6). Further- 
more, examination of endogenous El A-like activity in 
P19 EC, END-P, and HCT116 cells by determining the 
activity of an E2A-promoter/CAT construct (Fig. 7) sug- 
gested a correlation between the presence of an ElA- 
like activity and the response of the RARP2 promoter 
to RA. 
Evidence for the Involvement of a Cellular ElA-Like 
Factor in RAW32 Promoter Activation 
The reported activation of the RARPP promoter by RA 
in, for example, CV-1 and COS-1 cells requires addi- 
tional expression of RARs and is weak compared to 
the level of activation found in P19 EC cells (72, 73). 
This indicates that in P19 EC cells, the conditions are 
optimal for RA-dependent promoter activation. The 
demonstrated high level of RXRB expression in P19 EC 
cells, which has been found to function as a coregulator 
of RAR-dependent promoter activation and increases 
transcriptional activation by high affinity binding of RAR- 
RXR heterodimers to RAREs (34) could partially ex- 
plain the strong RARP2 promoter activation in these 
cells. In addition, the results presented here suggest a 
role for the cellular equivalent of El A in activation of 
the RARP2 promoter in these cells, which could function 
as a coactivator in a similar way as El A. Moreover, the 
weak or even absent promoter response to RA in 
differentiated cells could then be explained by the loss 
of El A-like activity upon differentiation. The evidence 
for this hypothesis is as follows. 1) The examination of 
the presence of an El A-like activity in P19 EC, END-P, 
and HCT116 cells revealed a correlation between the 
presence of El A-like activity and RAdependent RARP2 
promoter activation. In a recent report it was shown 
that the hepatoma cell line HepG2 contains a relatively 
high level of El A-like activity (74). This finding supports 
our hypothesis, since the RARB2 promoter has been 
shown to be relatively strongly activated by RA in these 
cells (11). 2) In END-2 and HCT116 cells, ElA is able 
to stimulate or even restore promoter activation by RA 
(Figs. 3 and 4). This suggests that ElA can substitute 
for the endogenous factor present in EC cells. 3) In P19 
EC ceils, cotransfection of small amounts of ElA 
expression vector had a repressive effect on RA-de- 
pendent activation, as determined on the -63/156 
RAR/32 promoter/CAT construct (Fig. 4). This can be 
explained by assuming that P19 EC cells contain an 
optimal amount of an El A-like factor, and by additional 
expression of El A, other participating factors are ti- 
trated out and become rate limiting. Candidates for 
such participating factors are RARs, RXRs, and TATA- 
binding factors. Interestingly, when the El A-sensitive 
CRE-containing -180/-63 promoter region was in- 
cluded in the reporter construct, the ElA 13s product 
could enhance activation of the promoter by approxi- 
mately 50% (Fig. 4). This indicates that the ElA inter- 
action sites of the protein that binds to this promoter 
region, probably ATF-2, are not saturated by the en- 
dogenous El A-like factor. 
Taken together, our results suggest an important 
role for the cellular equivalent of El A in the regulation 
of RARB2 promoter activation. Since El A-like activity 
has also been detected in mouse preimplantation em- 
bryos (60) it is possible that this activity contributes in 
vivo to the spatio-temporal expression of RARP2. 
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Possible Mechanism for ElA-Mediated RAW32 
Transactivation 
We have shown here in both stably transfected cell 
lines and cotransfection experiments that the -63/l 56 
promoter region alone, which contains the RARE and 
the TATA element and no other known functional ele- 
ments, was sufficient to mediate the stimulatoty effect 
of El A on RA-dependent RAR82 promoter activation 
(Figs. 4 and 5). Recently, Schijler et al. (75) reported 
that Ott-4 and El A are sufficient for distance-independ- 
ent activation of the basal transcription machinery. They 
propose a model in which El A or its cellular equivalent 
serves as a bridging factor between Ott-4 and the 
transcription initiation complex. Our results could be 
explained in a similar way by assuming that El A is able 
to interact with both TATA-binding factors and ligand- 
activated RARs, thereby facilitating activation of the 
promoter. Since the RARE is closely positioned to the 
TATA element, it would be interesting to investigate 
whether this interaction is distance independent in anal- 
ogy to the situation found with Ott-4 and ElA (75). In 
addition, the TATA-binding factor TFIID has recently 
been reported to be able to interact directly with ElA 
(76, 77). Whether such interactions are also possible 
with RARs remains to be proven. 
The involvement of a CRE-related sequence located 
in the -180/-63 region in the enhancement of RARP2 
promoter activation suggests the participation of mem- 
bers of the ATF/CREB transcription factor family (for 
review, see Ref. 66) in promoter activation by RA and 
El A. A specific member of this family, ATF-2, has been 
shown to be able to interact with El A directly (67). It is 
thought that the interaction of ElA with promoter- 
bound ATF-2 results in transcriptional activation by the 
positioning of the El A-activating region at the promoter 
(67). Such a mechanism could also account for the 
observed stimulatory effect of ElA found on CRE-P2. 
In addition, more evidence for the involvement of ATF- 
2 in RA- and El A-dependent RARP2 promoter activa- 
tion is provided by the fact that CR-3, which is absent 
in the El A 12s product, is involved in the interaction 
with ATF-2 (67), which correlates with and also provides 
an explanation for our observation that El A 13s and 
not 12s enhances promoter activation via CRE-/32 (Fig. 
5). 
Besides a possible direct interaction between ElA 
and the CRE-Be-binding activity, our results show that 
stable expression of El A in END-2 cells increases 
protein binding to the -180/-63 RARPP promoter re- 
gion and particularly induces CRE-Be-binding activity 
(Fig. 6). However, since in earlier studies we found that 
the increase in CRE-@P-binding activity induced by RA 
in P19 EC cells (see also Fig. 6) did not correspondingly 
result in an enhancement of CRE-@P-mediated tran- 
scription (65), it is too early to conclude that ElA 
enhances RARP2 promoter activation in a more indirect 
fashion by increasing CRE-BP-binding protein levels. 
Additional studies will be necessary to elucidate more 
precisely the manner in which El A enhances or restores 
RA-dependent RARP2 promoter activation. 
We propose a model for the way in which El A affects 
RA-dependent RARPP promoter activation, which com- 
bines the two mechanisms postulated for El A-me- 
diated transactivation earlier mentioned; El A affects 
RARPP promoter activation by functioning as a bridging 
factor between RARs or attached coregulators (RXRs) 
and the basal transcription machinery and enhances 
promoter activity further by interaction with ATF-2. 
MATERIALS AND METHODS 
Cells and Plasmids 
The cells (END-2, END-2 ElA, P19 EC, HCT116, and 293) 
used in the experiments were cultured on gelatin-coated 
dishes in a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium 
and Ham’s F-l 2 containing 7.5% fetal calf serum. 
A number of the CAT constructs used in transient transfec- 
tion assays have been described previously (28). CAT con- 
structs encomoassina nucleotides -335 to 156. -180 to 156. 
and -63 to 156 of tLe human RAR(32 promotk were gener: 
ated by subsequently subcloning a Ddel-BarnHI, a /-/pall- 
BarnHI, and a Smal-BamHI promoter fragment in the promot- 
erless pKTCAT vector. 
The -180/156 CAT construct containing either a mutated 
CRE- or TRE-related sequence was generated by site-directed 
mutagenesis using the Altered Sites In Vitro Mutagenesis 
System Kit (Promega, Madison, WI). Briefly, single-stranded 
DNA derived from the vector pSELECT inserted with the /-/pall- 
BamHl promoter fragment functioned as a template for muta- 
genesis using the synthetic oligodeoxynucleotides 5’- 
ATCCTGGGAGTTGGaGATGTtAGACTAGTTGGGTC3’or 5’- 
ATGTCAGACTAGTgtGGTCAlTTGAAGG-3’ encompassing 
nucleotides -112 to -79 or -97 to -70 of the human RARPP 
promoter, respectively, and with the altered bases shown in 
lowercase letters. In a consensus CRE or TRE, these altera- 
tions have been shown to abolish the function of these ele- 
ments (68, 76). 
The adenovirus E2A promoter-containing CAT construct, 
pSCAT, and the ElA (Ad2) expression vectors pEIASV, pElA 
12s. and pElA 13s. have been previously described (79,80). 
Plasmids used for the generation of 32P-labeled riboprobes 
contained murine RARa-, -p-, and -r-specific cDNA subfrag- 
ments (a 129-bp Sstl-Pstl fragment, a 116-bp EcoRI-Pstl frag- 
ment, and a 202-bp Ddel- Apal fragment, respectively) and a 
58-bp Haelll fragment obtained from murine glyceraldehyde- 
3-phosphate dehydrogenase (GAPDH) cDNA subcloned in the 
pBluescript vector SK- (Stratagene, La Jolla, CA) (81). 
RNA Isolation and RNase Protection Analyses 
Total cellular RNA was isolated using the acid-phenol single 
step method (82). 
Complementary 32P-labeled riboprobes directed against part 
of the C and D regions (RARa), the F region (RAR@), and part 
of the E and total F regions (RARr) were transcribed using T3 
or T7 RNA polymerases. Probes (1 O”-1 O5 cpm) were simulta- 
neously hybridized to total RNA (15 pg) overnight at 45 C in a 
buffer containing 80% (vol/vol) formamide, 40 mM piperazine- 
N,N’-bis-(2ethanesulfonic acid) (pH 6.4), 0.4 M NaCI, and 1 
mM EDTA. Subsequently, samples were digested with RNase 
Tl for 30 min at 37 C, treated with 0.1 mg/ml proteinase-K 
and 0.5% sodium dodecyl sulfate, and extracted with phenol. 
After ethanol precipitation, the samples were run on a 6% 
polyacrylamide sequencing gel. The fixed gel was exposed at 
-80 C for 3 days to x-ray film using an intensifying screen. A 
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GAPDH complementary riboprobe was always included in the 
assay to correct for possible differences in the amount of RNA 
loaded in each lane (83). Transcript levels were quantified by 
using a Molecular Dynamics Phospho lmager with Image 
Quant software. 
Transient Transfection Assays 
END-P, END-2 ElA, P19 EC, HCT116, and 293 cells cultured 
on gelatin-coated dishes (diameter, 3.5 cm) were transfected 
by calcium phosphate coprecipitation (84) using 10 pg CAT 
reporter plasmid DNA and varying amounts of El A expression 
vectors in combination with 1 pg SVP-LacZ as an internal 
control. After 16 h, fresh medium was added to the cells 
together with RA (final concentration, 1 Oe6 M) when appropri- 
ate. Cells were harvested 24 h later and assayed for CAT 
activity, as previously described (85). The reaction products 
separated by TLC were quantified by using a Molecular Dy- 
namics Phospho lmager (Eugene, OR) with Image Quant soft- 
ware. After normalizing transfection efficiency with the LacZ 
activity, CAT activity is expressed as the percentage conver- 
sion of the total amount of [‘4C]chloramphenicol into its ace- 
tylated products. When using the p2CAT reporter plasmid, 
CAT activity is depicted as the percentage of that of the 
control, &actin/CAT, expression of which is not modulated 
during differentiation. Routinely, transfection experiments 
were repeated at least three times. 
Gel Retardation Assays 
Nuclear protein extracts were prepared by the miniscale 
method, as described by Lee et al. (86). Protein concentrations 
were determined by the Bio-Rad protein assay according to 
the manufacturer’s protocol. 
The sequences of the double stranded oligonucleotides 
used in the assay were: CRE-B2, TGAGTTGGTGATGTCA- 
GACTAG; and RARE-BP, CCGGGTAGGGTTCACCGAA- 
AGT-TCACTCG. 
The -180/-63 RAR/32 promoter fragment used as a probe 
was generated by labeling the cohesive ends with [@PI 
deoxy-ATP using the Klenow fragment of DNA polymerase-I, 
followed by gel filtration using Sephadex G-50 spin columns 
(Pharmacia, Piscataway, NJ). 
The electrophoretic mobility shift assay used is based on 
the procedures described by Fried and Crothers (87) with 
slight modifications. Nuclear extracts (4 pg) were incubated in 
a reaction buffer (20 ~1) containing 16 rni Tris-HCI (pH 8.0) 
0.1 mM EDTA. 75 mM KCI, 10% (vol/vol) olvcerol, 1 mM 
dithiothreitol, O:l mg/ml poly-(dldC),‘ 106 ng/mi pUCl8 plas- 
mid DNA, and 0.1 ng 32P-labeled DNA fragment (SA, 1 x lOa/ 
pg) at room temperture for 20 min. An equal volume of loading 
buffer, containing 20% (vol/vol) Ficol, was added, and the 
mixture was immediately ioaded onto a 4% polyacrylamide gel 
and electrobhoresed in 0.5 x TBE (25 mM Tris. 25 mM boric 
acid, and 1 ‘mrv EDTA) for 4 h. The gel was fixed in 10% (vol/ 
vol) methanol-l 0% (vol/vol) acetic acid, dried, and exposed to 
Kodak XAR film for 2 days. 
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